Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches.
Sign Up to like & getrecommendations! Published in 2023 at "mAbs"
DOI: 10.1080/19420862.2023.2200540
Abstract: With the growing significance of antibodies as a therapeutic class, identifying developability risks early during development is of paramount importance. Several high-throughput in vitro assays and in silico approaches have been proposed to de-risk antibodies… read more here.
Keywords: throughput vitro; developability risks; high throughput; identifying developability ... See more keywords